This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lifshitz & Miller Law Firm Announces Investigation Of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. And NII Holdings, Inc.

NEW YORK, March 18, 2014 /PRNewswire/ --

CytRx Corporation

Lifshitz & Miller  announces that a class action was filed in the United States District Court for the Central District of California, alleging CytRx Corporation ("CYTR") issued false and misleading statements during the period between November 22, 2013 and March 13, 2014.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that that numerous articles praising CytRx stock were paid stock promotions.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

DURECT Corporation

Lifshitz & Miller  announces that it is investigating potential claims against the officers and board of DURECT Corporation ("DRRX").  On February 12, 2014, the Company disclosed that the FDA had issued a Complete Response Letter for the Company's product candidate, POSIDUR.  The Complete Response Letter means that the FDA will not approve POSIDUR's application for marketing approval in its current form.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (516) 493-9780 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Hastings Entertainment, Inc.

Lifshitz & Miller  announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Hastings Entertainment, Inc. ("HAST") to Draw Another Circle, LLC and Hendrix Acquisition Corp., which are each wholly-owned, directly or indirectly, by Joel Weinshanker in an all-cash transaction for $3.00 per share or approximately $21.4 million.

Lifshitz & Miller's investigation is focused on whether the HAST directors are acting in shareholders best interest.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs